PMID- 24266347
OWN - NLM
STAT- MEDLINE
DCOM- 20140714
LR  - 20191112
IS  - 1040-8401 (Print)
IS  - 1040-8401 (Linking)
VI  - 33
IP  - 6
DP  - 2013
TI  - Therapeutic dendritic cell-based cancer vaccines: the state of the art.
PG  - 489-547
AB  - Dendritic cells (DCs) are the most potent professional antigen-presenting cells, 
      capable of initiating proper adaptive immune responses. Although 
      tumor-infiltrating DCs are able to recognize cancer cells and uptake tumor 
      antigens, they often have impaired functions because of the immunosuppressive 
      tumor milieu. Therefore, DCs are targeted by therapeutic means either in vivo or 
      ex vivo to facilitate tumor antigen presentation to T cells and induce or promote 
      efficient antitumor immune responses in cancer patients. This immunotherapeutical 
      approach is defined as specific active tumor immunotherapy or therapeutic cancer 
      vaccination. In this review we briefly discuss general aspects of DC biology, 
      followed by a thorough description of the current knowledge and optimization 
      trends of DC vaccine production ex vivo, including various approaches for the 
      induction of proper DC maturation and efficient loading with tumor antigens. We 
      also discuss critical clinical aspects of DC vaccine application in cancer 
      patients, including protocols of administration (routes and regimens), 
      individualization of tumor immunotherapy, prediction and proper evaluation of 
      immune and clinical responses to immunotherapy, and the critical role of 
      combining tumor immunotherapy with other cancer treatment strategies to achieve 
      maximal therapeutic effects.
FAU - Strioga, Marius M
AU  - Strioga MM
AD  - Department of Immunology, Center of Oncosurgery, Institute of Oncology, Vilnius 
      University, Vilnius, Lithuania.
FAU - Felzmann, Thomas
AU  - Felzmann T
FAU - Powell, Daniel J Jr
AU  - Powell DJ Jr
FAU - Ostapenko, Valerijus
AU  - Ostapenko V
FAU - Dobrovolskiene, Neringa T
AU  - Dobrovolskiene NT
FAU - Matuskova, Miroslava
AU  - Matuskova M
FAU - Michalek, Jaroslav
AU  - Michalek J
FAU - Schijns, Virgil E J
AU  - Schijns VE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Crit Rev Immunol
JT  - Critical reviews in immunology
JID - 8914819
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Antigen Presentation
MH  - Antigens, Neoplasm/immunology
MH  - *Cancer Vaccines
MH  - Clinical Trials as Topic
MH  - Dendritic Cells/*immunology/transplantation
MH  - Humans
MH  - Immunotherapy/*methods
EDAT- 2013/11/26 06:00
MHDA- 2014/07/16 06:00
CRDT- 2013/11/26 06:00
PHST- 2013/11/26 06:00 [entrez]
PHST- 2013/11/26 06:00 [pubmed]
PHST- 2014/07/16 06:00 [medline]
AID - 7e31f36147bef9fb,4da59e1472598614 [pii]
AID - 10.1615/critrevimmunol.2013008033 [doi]
PST - ppublish
SO  - Crit Rev Immunol. 2013;33(6):489-547. doi: 10.1615/critrevimmunol.2013008033.